Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial

The Lancet Oncology
Paul C LyonConstantin C Coussios

Abstract

Previous preclinical research has shown that extracorporeal devices can be used to enhance the delivery and distribution of systemically administered anticancer drugs, resulting in increased intratumoural concentrations. We aimed to assess the safety and feasibility of targeted release and enhanced delivery of doxorubicin to solid tumours from thermosensitive liposomes triggered by mild hyperthermia, induced non-invasively by focused ultrasound. We did an open-label, single-centre, phase 1 trial in a single UK hospital. Adult patients (aged ≥18 years) with unresectable and non-ablatable primary or secondary liver tumours of any histological subtype were considered for the study. Patients received a single intravenous infusion (50 mg/m2) of lyso-thermosensitive liposomal doxorubicin (LTLD), followed by extracorporeal focused ultrasound exposure of a single target liver tumour. The trial had two parts: in part I, patients had a real-time thermometry device implanted intratumourally, whereas patients in part II proceeded without thermometry and we used a patient-specific model to predict optimal exposure parameters. We assessed tumour biopsies obtained before and after focused ultrasound exposure for doxorubicin concentration and ...Continue Reading

Citations

Jan 16, 2019·Radiology·Kevin W Dickey, Nicole Levi-Polyachenko
Feb 6, 2019·Nanomaterials·Stefania NardecchiaHouria Boulaiz
Apr 14, 2019·Transplant International : Official Journal of the European Society for Organ Transplantation·Annemarie WeissenbacherCarlo D L Ceresa
Oct 1, 2019·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Usman ArshadAndrew Owen
Aug 28, 2019·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Anjan MotamarryDieter Haemmerich
Dec 27, 2019·Current Opinion in Pediatrics·Caitlin Tydings, AeRang Kim
Jun 25, 2020·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·H Petra KokJohannes Crezee
Jan 18, 2020·Current Cancer Drug Targets·Kuldeep Rajpoot
Oct 18, 2019·Molecular and Clinical Oncology·Agata MikolajczykTanja Khosrawipour
May 31, 2019·Expert Opinion on Drug Delivery·Claudia Hill, Robert Carlisle
Sep 8, 2020·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Bingbing ChengRajiv Chopra
Aug 21, 2019·Anti-cancer Agents in Medicinal Chemistry·Paromita KunduSanjeeb K Sahoo
Apr 25, 2019·Nature Biomedical Engineering·Kullervo Hynynen
Oct 12, 2019·Nature Reviews. Cancer·Costas D ArvanitisRakesh K Jain
Jan 11, 2020·Frontiers in Bioengineering and Biotechnology·Oliver S Thomas, Wilfried Weber
Jan 11, 2019·Pharmaceutics·Catarina Oliveira SilvaCatarina Reis
Apr 10, 2019·Mini Reviews in Medicinal Chemistry·Sara Al BashaGhaleb Adnan Husseini
Mar 28, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Xiaoqin ChiJinhao Gao
Jun 26, 2020·Frontiers in Cell and Developmental Biology·Bin TuYongzhuo Huang
Aug 18, 2018·Cancer Chemotherapy and Pharmacology·Isabel SousaPaula Soares
Oct 28, 2019·Journal of Hematology & Oncology·Xiao-Dong Zhu, Hui-Chuan Sun
Mar 20, 2019·Pharmaceutics·Courtney van BallegooieDonald T Yapp
Aug 3, 2019·The Journal of the Acoustical Society of America·Michael D Gray, Constantin C Coussios
Dec 12, 2019·Frontiers in Bioengineering and Biotechnology·Priyanka TharkarWojciech Chrzanowski
Jul 28, 2020·Nanomaterials·Chunhua Yang, Didier Merlin
Dec 14, 2018·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Chenchen BingRajiv Chopra
Oct 2, 2019·Bioengineering & Translational Medicine·Aaron C Anselmo, Samir Mitragotri
Jun 12, 2020·Advanced Drug Delivery Reviews·Alberto A GabizonNinh M La-Beck
Oct 7, 2019·Drug Discovery Today·Mohammad NorouziFatemeh Atyabi
Feb 25, 2021·Scientific Reports·Paul Christopher LyonRobert Carlisle
Oct 24, 2020·Trends in Pharmacological Sciences·Andrei-Florian StoicaSiim Pauklin
Jun 24, 2020·Advanced Drug Delivery Reviews·Roland BöttgerShyh-Dar Li
May 26, 2021·Biomaterials Science·Mohammed Mehadi Hassan ChowdhuryMd Nurunnabi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy
fluorescence microscopy

Clinical Trials Mentioned

NCT02112656
NCT02181075
NCT02536183

Software Mentioned

OPTIMA
LabView
MatLab
PERCIST

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.